NNNN — Anbio Biotechnology Class A Ordinary Shares stock price, charts and financials

QT25Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
10.65
+0.75+7.58%
NNNNQT25Anbio Biotechnology Class A Ordinary Shares·NASDAQ
10.65+7.58%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E51.19EPS (ttm)0.19Insider Own-Shs Outstand43.89MPerf Week0.00%
Market Cap434.52MForward P/E-EPS next Y-Insider Trans-Shs Float39.69MPerf Month-19.84%
Enterprise Value426.76MPEG0.51EPS next Q-Inst Own-Short Float0.08%Perf Quarter-65.26%
Income8.47MP/S36.90EPS this Y-Inst Trans-Short Ratio0.88Perf Half Y-61.55%
Sales11.78MP/B14.41EPS next Y-ROA28.07%Short Interest31.58KPerf YTD-67.08%
Book/sh-P/C0.00EPS next 5Y-ROE27.49%52W High59.10 -81.98%Perf Year-76.43%
Cash/sh-P/FCF0.00EPS past 3/5Y31.98% -ROIC25.46%52W Low8.93 19.28%Perf 3Y-
Dividend Est.-EV/EBITDA65.89Sales past 3/5Y-27.89% -Gross Margin86.10%Volatility21.02% 14.87%Perf 5Y-
Dividend TTM-EV/Sales36.24EPS Y/Y TTM239.29%Oper. Margin65.20%ATR (14)1.85Perf 10Y-
Dividend Ex-Date-Quick Ratio344.31Sales Y/Y TTM50.00%Profit Margin72.09%RSI (14)36.37Recom-
Dividend Gr. 3/5Y-Current Ratio344.31EPS Q/Q-SMA20-3.02%Beta0.10Target Price-
Payout0.00%Debt/Eq0.00Sales Q/Q-16.67%SMA50-41.89%Rel Volume0.87Prev Close9.90
Employees27LT Debt/Eq-EarningsJul 07SMA200-59.26%Avg Volume38.03KPrice10.65
IPO DateFeb 19, 2025Option/ShortYes / YesEPS/Sales Surpr.-Net Debt/EBITDA-1.20Volume33,073Change7.58%
Latest News
Company

Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
Total Revenue12987244
Cost of Goods Sold Incl. D&A1123112
Gross Profit11863133
Selling, General and Administrative Excl. Other223120
Research and Development
000000
Other Operating Expense001000
Operating Income8622102
Interest Expense
000000
Unusual Expense
Non-Operating Income (Expense)010000
Net Income Before Taxes8622103
Income Taxes
000000
Consolidated Net Income8622103
Net Income From Continuing Operations8622103
Net Income8622103
EPS (Recurring)0.190.160.060.020.070.03
EPS (Basic, Before Extraordinaries)0.190.160.060.020.070.03
EPS (Diluted)0.190.160.060.010.070.03
EBITDA7622103
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio56.05187.94
Price To Sales Ratio39.05147.01
Gross Margin91.6788.8975.0042.8654.1775.00
Operating Margin66.6766.6725.0028.5741.6750.00
Net Margin66.6766.6725.0028.5741.6775.00
Shares Outstanding444442144144100
Market Capitalization4691,323
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.